Clinical trial
Bevacizumab and Sunitinib in Treating Patients With Solid Tumors
NCT00357318 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00357318 |
|---|---|
| Title | Bevacizumab and Sunitinib in Treating Patients With Solid Tumors |
| Official title | A Phase I Study of Bevacizumab in Combination With SU11248 |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological, Drug, Other |
| Interventions | sunitinib malate, bevacizumab, pharmacological study, laboratory biomarker analysis |
| Enrollment | 60 |
| Start date | Jun 1, 2006 |
| Primary completion | Jul 1, 2012 |
| First posted | Jul 27, 2006 |
| Last update posted | Feb 24, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: